November is Pet Cancer Awareness Month and we are dedicated to advancing innovative, targeted cancer treatments to help give our beloved companions more tomorrows. If your pet is facing a cancer diagnosis, there are options. Learn more at https://t.co/tJX5e4FHPt $RDGL
Thank you to our marketing team. Your work is bringing in more inquiries and turning them into real IsoPet patients, making a meaningful difference in the lives of pets and the families who love them. We will share more progress on the advances we are making with IsoPet as we move forward! $RDGL
@VivosIncUSA@RadioGel@IsoPetForCancer PS— you all better start making some better progress SOON. Update shareholders on when trials will start with Mayo.
$RDGL Mayo supports the RadioGel study and has voted to proceed.
The protocol is finalized with FDA conditions incorporated and is moving toward IRB submission.
IRB submission → IRB approval → study activation → first patient.
Progress.
Vivos is pleased to provide a business update on the continued advancement of its U.S. first-in-human feasibility study of RadioGel®, as the Mayo Clinic clinical process progresses toward IRB submission. $RDGL
https://t.co/dqQaOjg5Kp
Francis’ story truly touches our hearts. 💙 Diagnosed at 11yrs and given just 6 months to live, his mom refused to give up. They traveled to Johns Hopkins for treatment—and today, Francis is celebrating his 16th year. Every extra moment matters. 🐾 $RDGL
A major milestone for Vivos! @IsoPetForCancer is officially shipping from our APEL facility in Richland, WA! In-house production strengthens supply, quality and scalability while positioning Vivos for continued growth in the U.S. and worldwide. $RDGL
We are pleased to announce two significant operational milestones: the commencement of @IsoPetForCancer shipments from its new in-house U.S. production facility, and the receipt of authorization from AERB of India @RadioGel $RDGL
https://t.co/OHnzVq1m8P
Great coverage from the @TriCityHerald highlighting @RadioGel following our FDA IDE approval for human trials at the Mayo Clinic. This is an exciting milestone for our team and the future of precision cancer treatment. $RDGL
https://t.co/Bg9BDQ5bQH
With our recent FDA approval for our IDE to initiate human clinical trials for @RadioGel PRnT for the treatment of cancerous tumors we would like to announce a dedicated Investor Relations team to answer the many inquires during these exciting times. $RDGL
We always appreciate the opportunity to share the stories of our incredible patients when pet parents kindly give us permission. We’re thrilled to report that Harry is now cancer-free —a wonderful reminder of why we do what we do. @VivosIncUSA $RDGL
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
https://t.co/WsVKVWXhGY
We are excited to announce the acceptance by ACVS for our study on Postoperative Precision Radionuclide Brachytherapy for Incomplete Tumor Resection. This is a significant step forward for @IsoPetForCancer as a valuable tool in veterinary oncology. $RDGL
Following our FDA approval to initiate U.S. human trials with the Mayo Clinic, these words from our President, Mr. Brad Weeks, are truly encouraging. Our focus is now on advancing @RadioGel alongside our clinical partners. $RDGL
After years of dedication, Vivos Inc., a small American company, just received FDA IDE approval to start the first U.S. human feasibility study for RadioGel, a targeted injectable hydrogel therapy for cancer.
CEO Dr. Michael Korenko’s long-held dream is finally moving closer to helping patients who need better options. Real innovation from a small team with a big purpose. @elonmusk@rihanna@RealHughJackman@Cristiano@MrBeast@mcuban@JeffBezos
We are pleased to announce that we have received FDA approval to begin the US based first-in-human feasibility study using @RadioGel To read the full press release please visit https://t.co/FfgSTxpyrZ $RDGL